- Company
- Potential blockbuster drug Kerendia…1yr since reimbursement
- by Whang, byung-woo Mar 4, 2025 05:57am
- The prescription performance of Kerendia (finerenone), Bayer’s treatment for chronic kidney disease in adults with type 2 diabetes, has been increasing since it was granted reimbursement last year. With its monthly sales recording KRW 1 billion in the last month of last year, the drug is rapidly building up its performance, and given its gr
- Company
- Commercialization of PAH drug 'Winrevair' imminent
- by Eo, Yun-Ho Mar 4, 2025 05:57am
- The new drug 'Winrevair' for pulmonary arterial hypertension (PAH) is anticipated to land in South Korea. According to industry sources, MSD Korea's Winrevair (sotatercept), the world's first inhibitor therapy to treat PAH, has passed the secondary evaluation for the approval-reimbursement linkage process and now enters the last phase of
- Company
- Will COVID-19 vaccines be included in the NIP?
- by Moon, sung-ho Feb 28, 2025 05:58am
- The final results are gaining attention as the Korean government considers including COVID-19 vaccine to the National Immunization Program (NIP). The news presents a favorable opportunity for global pharmaceutical companies with vaccines. Consequently, these companies are focusing on publicizing the socioeconomic losses of COVID-19. Acc
- Company
- Lunit presents AI breast cancer Dx results at ECR 2025
- by Whang, byung-woo Feb 28, 2025 05:58am
- &160;On the 27th, Lunit, a medical artificial intelligence (AI) company, announced that it has presented 15 latest research achievements in the field of breast cancer diagnosis at the European Congress of Radiology 2025 (ECR 2025), which is being held in Vienna, Austria until the 2nd of next month. At the conference, Lunit presented 13 o
- Company
- Will patients taking osteoporosis drugs increase?
- by Moon, sung-ho Feb 28, 2025 05:58am
- With a denosumab biosimilar expected to enter the clinical trial site in Korea in earnest, changes in the treatment market are expected. According to industry sources on the 24th, the Ministry of Health and Welfare recently announced a preliminary administrative notice of the revision of the 'Detailed Standards and Methods for the Applic
- Company
- Will the SC injection be a new treatment option for IBD?
- by Son, Hyung Min Feb 28, 2025 05:58am
- The clinical accomplishments of subcutaneous formulation (SC) new drugs are being noticed in the inflammatory bowel diseases (IBD) area, including Crohn's disease and ulcerative colitis. Celltrion's Remsima SC clinical results have recently shown improved endoscopic and histologic remission rates. Janssen's Tremfya SC induction therapy also
- Company
- Will MSD’s rare cancer drug Welireg be reimbursed this time
- by Eo, Yun-Ho Feb 28, 2025 05:57am
- Attention is gathering as to whether the rare anticancer drug Welireg will succeed in its second attempt at reimbursement listing in Korea. According to industry sources, MSD Korea’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) will be presented to the Health Insurance Review and Assessment Service’s Ca
- Company
- Domestic approval application filed for 'Voranigo' in KOR
- by Eo, Yun-Ho Feb 27, 2025 05:57am
- New drug 'Voranigo' for malignant brain tumors has entered domestic approval procedure. According to the industry sources, Servier Korea has recently submitted approval application to the Ministry of Food and Drug Safety (MFDS) for Voranigo (vorasidenib). In Sepetember last year, this drug was designated an orphan drug in South Korea.
- Company
- Nexium challenged by P-CAB…attempts at regaining sales
- by Whang, byung-woo Feb 27, 2025 05:57am
- Proton pump inhibitors (PPIs) are being challenged by emerging P-CAB drugs. Therefore, Nexium's company is strengthening strategic partnerships to maintain Nexium's market position. The company continues partnering with Ildong Pharmaceutical and plans to continue collaboration based on its years of prescription experience. AstraZeneca
- Company
- Chong Kun Dang strengthens its oncology business
- by Kim, Jin-Gu Feb 27, 2025 05:57am
- Chong Kun Dang is tightening the reins on its oncology business. It recently acquired the right for the liver cancer drugs ‘Nexavar (sorafenib)' and ‘Stivarga (regorafenib)' and neutropenia drug ‘Neulapeg (pegfilgrastim)' in the recent month. The company expects the drugs to create synergy with its existing pipeline of anti-cancer dru
